الصفحة الرئيسية>>Signaling Pathways>> Chromatin/Epigenetics>> Epigenetic Reader Domain>>(R)-BAY1238097

(R)-BAY1238097

رقم الكتالوجGC34443

(R) -BAY1238097 هو R-isomer مع نشاط أقل لـ BAY1238097BAY1238097 هو مثبط قوي وانتقائي لربط BET بالهيستونات وله نشاط قوي مضاد للتكاثر في نماذج مختلفة من AML (سرطان الدم النخاعي الحاد) ونماذج MM (المايلوما المتعددة) من خلال التنظيم السفلي لمستويات c-Myc ونسخة المصب

Products are for research use only. Not for human use. We do not sell to patients.

(R)-BAY1238097 التركيب الكيميائي

Cas No.: 1564269-85-7

الحجم السعر المخزون الكميّة
10mM (in 1mL DMSO)
255٫00
متوفر
5mg
232٫00
متوفر
10mg
362٫00
متوفر
50mg
1159٫00
متوفر
100mg
1947٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

(R)-BAY1238097 is the R-isomer with lower activity of BAY1238097. BAY1238097 is a potent and selective inhibitor of BET binding to histones and has strong anti-proliferative activity in different AML (acute myeloid leukemia) and MM (multiple myeloma) models through down-regulation of c-Myc levels and its downstream transcriptome[1][2]. BET[1].

[1]. Lejeune, P., et al. (2015) Abstract 3524: BAY 1238097, a novel BET inhibitor with strong efficacy in hematological tumor models. Cancer Research, 75(15 Suppl), 884. [2]. Bernasconi E, et al. Preclinical evaluation of the BET bromodomain inhibitor BAY 1238097 for the treatment of lymphoma. Br J Haematol. 2017 Sep;178(6):936-948.

مراجعات

Review for (R)-BAY1238097

Average Rating: 5 ★★★★★ (Based on Reviews and 5 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for (R)-BAY1238097

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.